Onconetix is a commercial stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for clinicians and patients for oncology. The Company currently has Entadfi, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Onconetix was founded in 2018 and is based in Cincinnati, Ohio.
